Experience with Intravenous Plasma-Derived C1-Inhibitor in Pregnant Women with Hereditary Angioedema: A Systematic Literature Review
Brooks JP, Radojicic C, Riedl MA, Newcomer SD, Banerji A, Hsu FI. Experience with Intravenous Plasma-Derived C1-Inhibitor in Pregnant Women with Hereditary Angioedema: A Systematic Literature Review. The Journal Of Allergy And Clinical Immunology In Practice 2020, 8: 1875-1880.e3. PMID: 32251736, DOI: 10.1016/j.jaip.2020.03.009.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPlasma-derived C1-INHHereditary angioedemaC1-INHPregnant womenPlasma-derived C1 inhibitorC1 inhibitorTreatment guideline recommendationsFirst-line treatmentFavorable safety profileNumber of dosesEnglish-language articlesIntravenous plasmaGuideline recommendationsThird trimesterConsensus guidelinesSafety profileSpontaneous abortionPregnancySystematic reviewLanguage articlesAngioedemaLiterature searchData extractionTrimesterWomenLong-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trial
Levy DS, Farkas H, Riedl MA, Hsu FI, Brooks JP, Cicardi M, Feuersenger H, Pragst I, Reshef A. Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trial. Allergy, Asthma & Clinical Immunology 2020, 16: 8. PMID: 32042283, PMCID: PMC7001333, DOI: 10.1186/s13223-020-0409-3.Peer-Reviewed Original ResearchOpen-label extensionC1-INHHealthy babyFemale subjectsFirst trimesterSubgroup analysisHereditary angioedemaHAE-C1INHIU/Severe angioedema attacksSubcutaneous C1-INHPhase 3 trialParallel-arm trialAttacks/monthLong-term efficacyFemale sex hormonesPre-study periodSubgroup of subjectsHAE attacksRoutine prophylaxisEfficacy endpointEligible subjectsUneventful pregnancyAngioedema attacksSex hormones